Evidence map›Paper›PMID 38683404›Full record

ArticleMolecular biology reports2024

Safranal exerts a neuroprotective effect on Parkinson's disease with suppression of NLRP3 inflammation activation.

Wenping Yang, Yongyue Wei, Jin Sun, Caixia Yao, Fen Ai, Haixia Ding

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Wenping YangDivision of Neurology, Department of Geriatrics, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, NO. 300 Guangzhou Road, Nanjing, China.
Yongyue WeiDepartment of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.
Jin SunDepartment of Nuclear Medicine, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Caixia YaoDepartement of Endocrine, Nanjing Gao Chun People's Hospital, Nanjing, China.
Fen AiDepartment of Emergency, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, NO. 26 Shengli Street, Wuhan, Jiang'an District, China. doctoraifen@outlook.com.
Haixia DingDivision of Neurology, Department of Geriatrics, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, NO. 300 Guangzhou Road, Nanjing, China. dinghaixia2021@163.com.
Jiangsu Province Hospital · CNNanjing Medical University · CNCentral Hospital of Wuhan · CNGaochun People's Hospital · CN

Funding

Science, Education and Health Project Key Medical Talents Program of Jiangsu Province ZDRCA2016001
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is a common central nervous system neurodegenerative disease. Neuroinflammation is one of the significant neuropathological hallmarks. As a traditional Chinese medicine, Safranal exerts anti-inflammatory effects in various diseases, however, whether it plays a similar effect on PD is still unclear. The study was to investigate the effects and mechanism of Safranal on PD.

methodsThe PD mouse model was established by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine MPTP firstly. Next, the degree of muscle stiffness, neuromuscular function, motor retardation and motor coordination ability were examined by observing and testing mouse movement behavior. Immunofluorescence staining was used to observe the expression of tyrosine hydroxylase (TH). The dopamine (DA) content of the striatum was detected by High-performance liquid chromatography (HPLC). The expression of TH and NLRP3 inflammasome-related markers NLRP3, IL-1β, and Capase-1 were detected by Real-time Polymerase Chain Reaction (qRT-PCR) and western blotting (WB) respectively.

resultsThrough behavioral testing, Parkinson's mouse showed a higher muscle stiffness and neuromuscular tension, a more motor retardation and activity disorders, together with a worse motor coordination compared with sham group. Simultaneously, DA content and TH expression in the striatum were decreased. However, after using Safranal treatment, the above pathological symptoms of Parkinson's mouse all improved compared with Safranal untreated group, the DA content and TH expression were also increased to varying degrees. Surprisingly, it observed a suppression of NLRP3 inflammation in the striatum of Parkinson's mouse.

conclusionsSafranal played a neuroprotective effect on the Parkinson's disease and its mechanism was related to the inhibition of NLRP3 inflammasome activation.

Indexed as

CyclohexenesDisease Models, AnimalInflammasomesNeuroprotective AgentsNLR Family, Pyrin Domain-Containing 3 ProteinParkinson DiseaseTerpenes1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsCaspase 1Corpus StriatumDopamineInflammationInterleukin-1betaMaleMice1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineCaspase 1CyclohexenesDopamineInflammasomesInterleukin-1betaNeuroprotective AgentsNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mousesafranalTerpenesTyrosine 3-MonooxygenaseNeuroprotectiveNLRP3Parkinson’s diseaseSafranal

Identifiers

PMID38683404
PMCPMC11059006
OpenAlexW4396221852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.